Xymogen, Orlando, FL, has announced an exclusive partnership with Canada-based Acasti Pharma, with whom they will launch the worldwide distribution of LipiChol540, a physician-prescribed medical food to manage omega 3 phospholipid deficiency. The formula will be distributed by Pharmaceutix Medical Foods, a wholly owned subsidiary of Xymogen. Acasti’s focus is in the medical use of long-chain omega 3 phospholipids for treatment of chronic cardiovascular and cardiometabolic disorders. LipiChol540 contains high levels of omega 3 essential fatty acids and antioxidants and has become known as a nutrient-rich “superfood” because it is more easily absorbed into the body than fish oil.